{"id":{"repo_id":"msu","oai_identifier":"oai:d.lib.msu.edu:etd_391"},"canonical_url":"https://search.ndltd.org/etd/msu/oai:d.lib.msu.edu:etd_391","repository":{"repo_id":"msu","name":"Michigan State University","base_url":"https://d.lib.msu.edu/oai"},"display":{"title":"Risk of developing chronic beryllium disease and beryllium sensitization associated with HLA-DPB1 and DRB1 polymorphisms and magnitude of beryllium exposure","abstract":"Background: Beryllium exposure is a necessary but not sufficient cause of CBD and BeS. The presence of HLADPB1 Glutamine 69 and other polymorphisms were shown in previous studies to influence disease development. Our goal was to examine genetics and exposure effect in the development of BeS and CBD and progression from BeS to CBDMethods: DNA-based typing was conducted for all subjects (n=361) consisting of 61 CBD, 41 BeS, and 259 exact matched controls. Exposures were assessed through job history and industrial hygiene records.Results: Glutamine 69 increased the risk of Chronic Beryllium Disease and Beryllium Sensitization (OR respectively 25.7; 95% CI 6.1-108.5 and 6.4; 95% CI 2.4-17.1). Glutamine 71 had an important role in the development of BeS (OR 2.4; 95% CI 1.1-5.6) and was shown to be protective for CBD among Beryllium sensitized individuals (OR 0.38, 95% CI 0.16-0.87). There was no clear dose-response or interaction between genetics and exposure, but the matched controls without susceptible genes, although having the highest exposure, remained healthy.Conclusion: Glutamine 69 increased the odds of developing CBD and BeS. Glutamine 71 showed an important role in the development of BeS and possibly reducing the risk of progression to CBD. Further work to explore other polymorphisms is needed to assess exposure-genetic interactions and dose-response associations.","abstract_html":"Background: Beryllium exposure is a necessary but not sufficient cause of CBD and BeS. The presence of HLADPB1 Glutamine 69 and other polymorphisms were shown in previous studies to influence disease development. Our goal was to examine genetics and exposure effect in the development of BeS and CBD and progression from BeS to CBDMethods: DNA-based typing was conducted for all subjects (n=361) consisting of 61 CBD, 41 BeS, and 259 exact matched controls. Exposures were assessed through job history and industrial hygiene records.Results: Glutamine 69 increased the risk of Chronic Beryllium Disease and Beryllium Sensitization (OR respectively 25.7; 95% CI 6.1-108.5 and 6.4; 95% CI 2.4-17.1). Glutamine 71 had an important role in the development of BeS (OR 2.4; 95% CI 1.1-5.6) and was shown to be protective for CBD among Beryllium sensitized individuals (OR 0.38, 95% CI 0.16-0.87). There was no clear dose-response or interaction between genetics and exposure, but the matched controls without susceptible genes, although having the highest exposure, remained healthy.Conclusion: Glutamine 69 increased the odds of developing CBD and BeS. Glutamine 71 showed an important role in the development of BeS and possibly reducing the risk of progression to CBD. Further work to explore other polymorphisms is needed to assess exposure-genetic interactions and dose-response associations.","abstract_has_math":false,"creators":["Widyaningsih, Vitri"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Rosenman, Kenneth","Pathak, Dorothy","Gardiner, Joseph"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013","date_published":"2013","updated_at":"2026-11-18T18:42:01Z","subjects":["Glutamine","Beryllium--Physiological effect","Beryllium"],"languages":["English"],"rights":["In Copyright"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:391","isbn:9781303063497","isbn:1303063492","oclc:931732056","umi:1536965","local:Widyaningsih_grad.msu_0128N_12019"],"render_values":[{"text":"etd:391","href":null,"code":true},{"text":"isbn:9781303063497","href":null,"code":true},{"text":"isbn:1303063492","href":null,"code":true},{"text":"oclc:931732056","href":null,"code":true},{"text":"umi:1536965","href":null,"code":true},{"text":"local:Widyaningsih_grad.msu_0128N_12019","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://doi.org/doi:10.25335/dg29-0p24","outbound_label":"DOI","outbound_source":"dc:identifier","record_url":"https://doi.org/doi:10.25335/dg29-0p24","record_label":"Repository record","record_kind":"doi","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://d.lib.msu.edu/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Ad.lib.msu.edu%3Aetd_391","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Rosenman, Kenneth","Pathak, Dorothy","Gardiner, Joseph"]},{"key":"dc:creator","label":"Author","values":["Widyaningsih, Vitri"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2013"]},{"key":"dc:relation","label":"Dc Relation","values":["Electronic Theses & Dissertations"]},{"key":"dc:type","label":"Dc Type","values":["Text","Theses"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Glutamine","Beryllium--Physiological effect","Beryllium"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["English"]},{"key":"dc:rights","label":"Dc Rights","values":["In Copyright"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:391","isbn:9781303063497","isbn:1303063492","oclc:931732056","umi:1536965","local:Widyaningsih_grad.msu_0128N_12019","https://doi.org/doi:10.25335/dg29-0p24"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Background: Beryllium exposure is a necessary but not sufficient cause of CBD and BeS. The presence of HLADPB1 Glutamine 69 and other polymorphisms were shown in previous studies to influence disease development. Our goal was to examine genetics and exposure effect in the development of BeS and CBD and progression from BeS to CBDMethods: DNA-based typing was conducted for all subjects (n=361) consisting of 61 CBD, 41 BeS, and 259 exact matched controls. Exposures were assessed through job history and industrial hygiene records.Results: Glutamine 69 increased the risk of Chronic Beryllium Disease and Beryllium Sensitization (OR respectively 25.7; 95% CI 6.1-108.5 and 6.4; 95% CI 2.4-17.1). Glutamine 71 had an important role in the development of BeS (OR 2.4; 95% CI 1.1-5.6) and was shown to be protective for CBD among Beryllium sensitized individuals (OR 0.38, 95% CI 0.16-0.87). There was no clear dose-response or interaction between genetics and exposure, but the matched controls without susceptible genes, although having the highest exposure, remained healthy.Conclusion: Glutamine 69 increased the odds of developing CBD and BeS. Glutamine 71 showed an important role in the development of BeS and possibly reducing the risk of progression to CBD. Further work to explore other polymorphisms is needed to assess exposure-genetic interactions and dose-response associations.","Thesis (M.S.)--Michigan State University. Epidemiology, 2013","Includes bibliographical references (pages 74-79)"]},{"key":"dc:format","label":"Dc Format","values":["xi, 79 pages","application/pdf"]},{"key":"dc:title","label":"Title","values":["Risk of developing chronic beryllium disease and beryllium sensitization associated with HLA-DPB1 and DRB1 polymorphisms and magnitude of beryllium exposure"]}]}],"canonical_facts":{"dc:contributor":["Rosenman, Kenneth","Pathak, Dorothy","Gardiner, Joseph"],"dc:creator":["Widyaningsih, Vitri"],"dc:date":["2013"],"dc:description":["Background: Beryllium exposure is a necessary but not sufficient cause of CBD and BeS. The presence of HLADPB1 Glutamine 69 and other polymorphisms were shown in previous studies to influence disease development. Our goal was to examine genetics and exposure effect in the development of BeS and CBD and progression from BeS to CBDMethods: DNA-based typing was conducted for all subjects (n=361) consisting of 61 CBD, 41 BeS, and 259 exact matched controls. Exposures were assessed through job history and industrial hygiene records.Results: Glutamine 69 increased the risk of Chronic Beryllium Disease and Beryllium Sensitization (OR respectively 25.7; 95% CI 6.1-108.5 and 6.4; 95% CI 2.4-17.1). Glutamine 71 had an important role in the development of BeS (OR 2.4; 95% CI 1.1-5.6) and was shown to be protective for CBD among Beryllium sensitized individuals (OR 0.38, 95% CI 0.16-0.87). There was no clear dose-response or interaction between genetics and exposure, but the matched controls without susceptible genes, although having the highest exposure, remained healthy.Conclusion: Glutamine 69 increased the odds of developing CBD and BeS. Glutamine 71 showed an important role in the development of BeS and possibly reducing the risk of progression to CBD. Further work to explore other polymorphisms is needed to assess exposure-genetic interactions and dose-response associations.","Thesis (M.S.)--Michigan State University. Epidemiology, 2013","Includes bibliographical references (pages 74-79)"],"dc:format":["xi, 79 pages","application/pdf"],"dc:identifier":["etd:391","isbn:9781303063497","isbn:1303063492","oclc:931732056","umi:1536965","local:Widyaningsih_grad.msu_0128N_12019","https://doi.org/doi:10.25335/dg29-0p24"],"dc:language":["English"],"dc:relation":["Electronic Theses & Dissertations"],"dc:rights":["In Copyright"],"dc:subject":["Glutamine","Beryllium--Physiological effect","Beryllium"],"dc:title":["Risk of developing chronic beryllium disease and beryllium sensitization associated with HLA-DPB1 and DRB1 polymorphisms and magnitude of beryllium exposure"],"dc:type":["Text","Theses"]},"updated_at":"2026-11-18T18:42:01Z"}